Sonnet announces successful completion of the discovery phase for its next preclinical pipeline candidate (son-1410)

Son-1410 (il18-fhab-il12), a bispecific combination of interleukins 18 and 12, was selected based on data generated in a mouse melanoma study comparing three bispecific constructs selection of the asset was performed with input from sonnet's scientific advisory board an ind submission for son-1410 is anticipated during the second half of 2022 princeton, nj / accesswire / august 30, 2021 / sonnet biotherapeutics holdings, inc., (nasdaq:sonn) a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it has selected a novel development candidate after completing comparative studies in a mouse melanoma model. the candidate represents sonnet's second bispecific compound integrating interleukin 12 (il-12) with the company's fully human albumin binding (fhab) platform.
SONN Ratings Summary
SONN Quant Ranking